Latest news with #CST
Daily Mirror
3 days ago
- Business
- Daily Mirror
Chelsea fans accuse club of 'exploiting loyalty' as Premier League make contact
Chelsea have increased ticket prices by an average of 17 per cent in the last two seasons and the club's official supporters' group have vented their fury at the ownership, accusing them of alienating the core fanbase Chelsea fans have slammed a new ticket pricing strategy and accused the club of 'exploiting the loyalty of those people who are the lifeblood of the club.' The Chelsea Supporters' Trust says season ticket prices have increased by an average of 17 per cent in the last two years and members are angry at new booking fees, decreasing concessions and a £60 'priority' membership. They have now surveyed their members and the CST says it is joining the Football Supporters' Association's nationwide Stop Exploiting Loyalty campaign. A CST spokesperson said: 'Piece by piece, Chelsea FC is alienating a large part of our core fan base with decisions that will slowly force supporters to pick and choose which games they attend. 'The exploitation of members is also a worry, and we are deeply concerned that the increasingly bad deal that members have will negatively impact our club for generations to come. 'This should be a huge wake-up call to the owners and the senior leadership team within the club. Supporters are rejecting the decisions made by the club and are evidently unhappy with the current path being taken. 'Not only is it ethically wrong to exploit the loyalty of the lifeblood of our club, but it is strategically short-sighted and obliterates any trust or goodwill that had started to be built by recent positive initiatives.' The Premier League has already contacted Chelsea over complaints that a ticket resale company part-owned by co-owner Todd Boehly, Vivid Seats, was selling seats for sky high prices. Chelsea reported a pre-tax profit of £128.4m last year and could earn £97m from the Club World Cup. Less than 30 per cent of members thought prices were acceptable. The CST added: 'Despite record-breaking profits, Chelsea FC has broken its commitment to 'maximise all other revenue streams before increasing costs for supporters' by introducing a range of new policies that hit the pockets of loyal supporters. 'The CST has consistently warned the club that time after time they are making poor choices that infuriate supporters. This statistic is therefore really alarming and cannot be ignored.' Chelsea said recently they had consulted with the Fan Advisory Board and added: 'As a club, our priority is to ensure that we are making the right decisions for the long-term sustainability and success of the club.' Join our new WhatsApp community and receive your daily dose of Mirror Football content. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. If you're curious, you can read our Privacy Notice.
BBC News
4 days ago
- Politics
- BBC News
Fans urge Supporters' Trust to join campaign around ticketing
The results of a survey of Chelsea fans has urged the Chelsea Supporters' Trust (CST) to join the Football Supporters' Association (FSA)'s 'Stop Exploiting Loyalty' comes as the club introduces a range of new policies around ticketing and membership, including a new booking fee per ticket and a priority membership to the CST's survey, almost 90% of respondents instructed the trust to join the FSA's campaign which was launched in 2024 and has seen a number of protests across different supporter groups take place in support of the CST say that Blues fans have indicated they do not believe their loyalty is "understood or appreciated by the club" and that they will now "take action to highlight how supporters are continuously being overlooked".The CST said: "Piece by piece, Chelsea FC is alienating a large part of our core fan base with decisions that will slowly force supporters to pick and choose which games they attend."The exploitation of members is also a worry, and we are deeply concerned that the increasingly bad deal that members have will negatively impact our club for generations to come."This should be a huge wake-up call to the owners and the senior leadership team within the club. Supporters are rejecting the decisions made by the club and are evidently unhappy with the current path being taken."Not only is it ethically wrong to exploit the loyalty of the lifeblood of our club, but it is strategically short-sighted and obliterates any trust or goodwill that had started to be built by recent positive initiatives."
India Today
4 days ago
- Science
- India Today
India gets first school made of sugarcane waste bricks in Noida
Ever heard of a school being made up of waste from sugarcane? No, it is real and happened in Noida, Uttar Pradesh. A new school building made entirely from Sugarcrete -- a construction block made from sugarcane waste -- has opened in Noida, which became a turning point in low-carbon architecture in project is a collaboration between the University of East London (UEL), Indian manufacturer Chemical Systems Technologies (CST), and Panchsheel Balak Inter College (PBIC), where the structure now stands at the top in sugarcane production globally, which means it is now possible to use alternatives to soil-made bricks in construction. This can help achieve sustainability goals and also prevent soil ALTERNATIVE TO BRICK?Sugarcrete was developed in 2023 by UEL researchers Alan Chandler and Armor Gutierrez Rivas. Made from bagasse -- the dry pulp left over after extracting juice from sugarcane -- and mixed with mineral binders, it offers a carbon footprint six times lower than traditional fired is the first time Sugarcrete has been used to construct a full-scale classroom, and the team behind it believes it will not be the classroom, standing on a concrete base, has walls made of interlocking Sugarcrete blocks, which are held together with lime mortar. (Image: University of East London) advertisementIts roof, supported by a steel frame, includes a clerestory window that allows natural light to enter and provides ventilation. The design also includes a veranda to shield students during the monsoon."More than just a material, Sugarcrete is a system for inclusive, low-carbon development," said Rivas, who leads the team. "This school is a real-world test, proving how design can serve both the environment and the community." he further EXPANDS SUGARCANE RESEARCH WITH NEW PROJECTS ACROSS INDIAThe school in Noida is not the end of the road. The same team is now building another Sugarcrete-based facility in Hisar, Haryana, in collaboration with the education NGO Paryatan centre will cater to 150 vulnerable children, focusing on learning and students and staff also held workshops in Hisar with local polytechnic students and researchers, exploring how India's native fibres and natural dyes could be used to regulate indoor a visit to CCS Haryana Agricultural University, UEL signed an MoU to conduct joint research into agro-waste also touched on shared training and future curriculum MoU was also signed between CST founder Sunil Shingal and UEL to expand the use of Sugarcrete across joint study group was also formed with Delhi Technological University to monitor the classroom's performance.'This is not just a building; it's a step toward a new way of thinking,' said Alan Chandler. 'It shows that communities, institutions, and industries can come together to build differently -- and better.'With momentum building, Sugarcrete may soon become a common sight across India's towns and villages.- Ends
Business Wire
4 days ago
- Business
- Business Wire
MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board
CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc. (NYSE American: MAIA) ('MAIA', the 'Company'), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (CST) in HCC and may participate in future investigator sponsored trials (IST). 'Drs. Pinato and Fulgenzi are scientific experts on inflammation as a pathogenic and prognostic mechanism in primary liver cancers. Together, their research has focused on improving the treatment of HCC, particularly with the use of anti-cancer immunotherapy,' said MAIA Chairman and CEO Vlad Vitoc, M.D. 'They will bring a wealth of knowledge to our SAB, with specialized expertise that will inform our plans and preparations for our upcoming clinical program in HCC. 'By the end of this year, we expect to have all required approvals to begin enrolling patients in a HCC trial,' Dr. Vitoc added. MAIA was granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for ateganosine as a treatment for HCC in 2022. ODDs can provide up to seven years of market exclusivity. Dr. David Pinato is a clinician scientist in the Department of Surgery and Cancer at Imperial College London and a consultant oncologist at Imperial College Healthcare NHS Trust. As Director of Developmental Cancer Therapeutics at Imperial College, he leads a translational research program focused on the early clinical implementation of novel experimental anticancer therapies with particular emphasis on anti-cancer immunotherapy. Dr. Pinato's research efforts in liver cancer have been recognized by the American Society of Clinical Oncology (ASCO) and the Society for Immunotherapy of Cancer (SITC). He has received awards by the British Society of Pharmacology and the Royal Society of Medicine, and fellowships by the European School of Oncology and Fulbright Program. Dr. Pinato completed his core medical training across some of the busiest acute hospitals in London and was elected to the Royal College of Physicians (MRCP). His research has been published in leading journals in the field including the Journal of Clinical Oncology, Annals of Oncology, Hepatology and many others. Dr. Pinato lectures internationally in the field of molecular oncology with a specific interest in HCC and acts as a reviewer for several peer-reviewed journals including The Lancet, Cancer Discovery, Hepatology and Journal of Hepatology. Dr. Claudia Fulgenzi is a specialist in medical oncology at Imperial College London, with dedicated professional interest in the field of immune-oncology and gastro-intestinal cancers, particularly hepatic-biliary malignancies. Dr. Fulgenzi graduated in medicine from the University of Rome Tor Vergata and subsequently specialized in medical oncology at the University Campus Bio Medico of Rome, Italy. Her contributions to the field have been recognized with prestigious awards including the ASCO Merit Award, the Young Investigator award by the International Liver Cancer Association (ILCA) and the American Society of Clinical Oncology. Dr. Fulgenzi is actively engaged in clinical practice in London, serving as an honorary consultant in oncology at Chelsea and Westminster Hospital and as a specialty doctor in the early phase clinical trial unit at Hammersmith Hospital. In these capacities, she conducts clinical and translational research, contributes to clinical trial design, and provides expert medical guidance to cancer patients. Hepatocellular carcinoma is the most frequently occurring primary liver tumor representing approximately 90% of all liver cancers. HCC currently ranks 5th by incidence and 3rd by mortality on a global scale. About Ateganosine Ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) is a first-in-class investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies. The modified nucleotide 6-thio-2'-deoxyguanosine induces telomerase-dependent telomeric DNA modification, DNA damage responses, and selective cancer cell death. Ateganosine-damaged telomeric fragments accumulate in cytosolic micronuclei and activates both innate (cGAS/STING) and adaptive (T-cell) immune responses. The sequential treatment of ateganosine followed by PD-(L)1 inhibitors resulted in profound and persistent tumor regression in advanced, in vivo cancer models by induction of cancer type–specific immune memory. Ateganosine is presently developed as a second or later line of treatment for NSCLC for patients that have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors. About MAIA Biotechnology, Inc. MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is ateganosine (THIO), a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit Forward Looking Statements MAIA cautions that all statements, other than statements of historical facts contained in this press release, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as 'may,' 'might,' 'will,' 'should,' 'could,' 'expect,' 'plan,' 'anticipate,' 'believe,' 'estimate,' 'project,' 'intend,' 'future,' 'potential,' or 'continue,' and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. For example, all statements we make regarding (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi) the size and growth potential of the markets for our product candidates and our ability to serve those markets, and (vii) our expectations regarding our ability to obtain and maintain intellectual property protection for our product candidates, are forward looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement. Any forward-looking statement speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. In this release, unless the context requires otherwise, 'MAIA,' 'Company,' 'we,' 'our,' and 'us' refers to MAIA Biotechnology, Inc. and its subsidiaries.
Scottish Sun
5 days ago
- Business
- Scottish Sun
Chelsea asked to explain relationship with controversial ticket website Todd Boehly part-owns after fan fury
Chelsea fans have labelled the company's association with the club as a "breach of trust" TODD ONE OUT Chelsea asked to explain relationship with controversial ticket website Todd Boehly part-owns after fan fury Click to share on X/Twitter (Opens in new window) Click to share on Facebook (Opens in new window) CHELSEA have been asked to explain their relationship with ticket resale site Vivid Seats after fan fury towards Todd Boehly. Blues co-owner Boehly is a director and investor in the American firm, which listed some individual Premier League tickets for up to £20,000 last season. Sign up for Scottish Sun newsletter Sign up 3 Chelsea have been asked to explain their relationship with ticket resale site Vivid Seats after fan fury towards Todd Boehly Credit: Alamy 3 Premier League CEO Richard Masters has confirmed that the league have written to Chelsea about the issue Credit: Getty The Chelsea Supporters' Trust (CST) wrote to Premier League chief executive Richard Masters in March saying they were "dismayed" by the connection. Blues supporters also said Boehly's position felt like a "breach of trust" and a "clear conflict of interest". Vivid Seats, who often sell tickets at inflated rates, is listed on the Premier League website as an unauthorised ticket website. The league has even told fans to "exercise extreme caution" when purchasing from Vivid Seats. READ MORE ON CHELSEA HAD EN-UFF Chelsea legend Duff 'abruptly quits as manager' despite Champions League hopes Masters met with the Football Supporters Association last month and revealed the Premier League have now contacted Chelsea and that the matter is "ongoing". The minutes from the meeting between the FSA and Masters, which included CST vice-chair Dom Rosso, read: "RM [Masters] confirmed the PL had written to Chelsea to seek clarification on the club's position with the matter ongoing. "RM advised the PL would reply to CST once the PL had concluded its discussions with the club." Chelsea took strong action against ticket touts earlier this season. Join SUN CLUB for the Chelsea Files every Tuesday plus in-depth coverage and exclusives from Stamford Bridge They told supporters in an email that they had cancelled 1,500 membership accounts where a link to ticket touting had been identified. Chelsea have been contacted for comment.
